1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
FDC Limited

FDC Limited

FDC.BO
FDC LimitedIN flagBombay Stock Exchange
429.50
INR
-0.45
- -
70.02BMarket Cap
FDC Limited
FDC.BO
(Bombay Stock Exchange)

Recent

price

429.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
38.23
38.49
42.16
47.09
49.78
55.53
56.61
59.8
62.06
77.63
77.84
90.24
106.96
118.32
129.51
133.38
133.49
Revenue per Share
8.11
7.3
8.51
7.59
8.33
9.48
10.6
9.76
9.74
13.94
17.73
12.82
11.67
18.59
16.39
17.29
17.31
Basic EPS, GAAP
5.38
6.26
6.94
-0.08
4.25
-7.54
7.22
6.35
4
12.74
8.5
1.72
2.52
7.76
13.57
0.85
- -
Free Cash Flow per Basic Share
1.75
2
2.01
2.24
2.25
5.42
- -
2.71
- -
0.8
- -
- -
0.01
0.01
4.98
4.98
- -
Dividend per Share
16.52
20.08
23.39
26.1
35.06
36.29
46.88
53.83
64.59
78.4
95.74
109.3
90.69
108.11
120.3
1
1
Book Value per Share
32.68
37.38
42.78
47.25
56.65
60.65
70.87
71.32
82.5
89.58
101.75
115.62
118.87
127.45
139.88
152.44
152.58
Tangible Book Value per Share
186
184
182
178
178
178
178
178
174
172
170
169
166
164
163
163
163
Basic Weighted Avg Shares
7,117
7,074
7,691
8,397
8,853
9,874
10,066
10,633
10,824
13,356
13,231
15,233
17,778
19,429
21,081
21,709
21,709
Sales/Revenue/Turnover
20.94
21.02
19.91
21.68
18.11
19.78
20.75
18.62
18.27
21
22.39
14.23
11.94
15.37
12.86
13.21
12.6
Operating Margin (%)
174
184
279
249
388
337
346
351
332
375
378
373
389
399
537
592
592
Depreciation Expense
1,509
1,341
1,552
1,353
1,481
1,687
1,885
1,735
1,698
2,399
3,013
2,164
1,940
3,052
2,668
2,814
2,814
Net Income, GAAP
13.96
22.13
21.52
38.03
27.26
27.34
25.13
27.89
28.25
25.03
22.32
25.3
24.82
23.01
25.31
24.87
24.87
Effective Tax Rate (%)
21.2
18.96
20.18
16.12
16.73
17.08
18.73
16.32
15.69
17.96
22.77
14.21
10.91
15.71
12.66
12.96
12.96
Profit Margin (%)
3,234
3,071
2,569
2,563
3,811
3,599
5,289
5,109
5,609
6,808
7,303
7,280
7,153
7,559
7,271
7,684
7,684
Working Capital
25
20
15
11
9
8
7
6
5
96
75
253
208
126
121
106
106
LT Debt
6,164
6,954
7,842
8,453
10,096
10,825
12,702
12,761
14,452
15,474
17,340
19,564
19,814
20,972
22,811
24,851
24,851
Total Equity
22.27
17.59
16.22
13.82
12.55
13.5
13.15
11.07
10.31
13.85
13.8
8.62
7.95
11.12
9.15
8.96
8.55
Return on Invested Capital (%)
90.85
39.45
38.88
30.51
27.31
26.66
25.56
19.45
16.36
19.44
20.2
12.42
11.54
18.5
14.31
28.36
28.36
Return on Capital (%)
92.52
39.64
39
30.34
27.21
26.59
25.49
19.38
16.3
19.38
20.25
12.46
11.58
18.6
14.29
28.51
28.51
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
99
- -
49
LT Borrowings
- -
- -
- -
LT Finance Leases
108
- -
106
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
163
- -
163
Market Capitalization
71,852
68,802
52,235

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
11,336
- -
11,325
Cash, Cash Equivalents & STI
4,523
- -
5,323
Accounts Receivable, Net
1,643
- -
1,517
Inventories
4,351
- -
3,553
Total Current Liabilities
3,800
- -
3,641
Payables & Accruals
- -
- -
- -
ST Debt
99
- -
49
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.78%
7.53%
8.94%
Free Cash Flow
8.24%
29.61%
-93.71%
Net Income, GAAP
8.02%
2.33%
5.49%
Sales/Revenue/Turnover
8.45%
10.52%
2.98%
Total Cash Common Dividend
- -
- -
-0.13%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,364
4,864
4,582
4,543
19,429
2025
6,383
5,138
4,641
4,919
21,081
2026
6,484
4,730
4,647
5,848
21,709

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6.62
4.22
4.86
- -
18.59
2025
7.31
4.43
2.28
2.38
16.39
2026
7.45
1.75
1.74
6.35
17.29

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
4.98
2026
- -
- -
- -
- -
4.98
Similar Companies
Chugai Pharmaceutical Co., Ltd. (CHGCY)
Shinnihonseiyaku Co., Ltd. (4931.T)
Norris Medicines Limited (NORRIS.BO)
Welcia Holdings Co., Ltd. (3141.T)
Ipsen S.A. (IPSEF)
Middle East Pharmaceutical Industries Company (4016.SR)
Business
FDC Limited (FDC.BO) manufactures and markets a broad portfolio of pharmaceutical formulations and active pharmaceutical ingredients. The company offers oral rehydration solutions including Electral and Electral-Z; energy drinks such as Enerzal; antibiotics like Zifi, Zathrin and Zoxan; anti-infectives comprising Zocon fluconazole capsules and topical antifungals; ophthalmics such as Iotim timolol eye drops, Moxi moxifloxacin eye drops, Dorzolamide eye drops and combination glaucoma therapies; anti-ulcerants; analgesics-antipyretics; corticosteroids; anti-coagulants; nutritional supplements including Vitcofol iron-folic acid injections and Simyl MCT Oil; and consumer healthcare products encompassing dusting powders like Mycoderm-C and nutraceuticals. FDC Limited operates manufacturing facilities in Waluj, Roha, Sinnar, Baddi, Goa and other sites across Maharashtra, Goa and Himachal Pradesh, with in-house research and development centers accredited by the Department of Science and Technology; the company exports over 300 products to more than 50 countries including the United States, United Kingdom, South Africa, nations across Latin America, Africa, Asia, Europe and the Middle East. Founded in 1936 by Anand Chandavarkar and headquartered in Mumbai, Maharashtra, FDC Limited maintains wholly owned subsidiaries FDC Inc. in the USA and FDC International Ltd. in the UK, alongside a joint venture in South Africa. In recent developments, FDC Limited sustains strong growth with annual revenues surpassing INR 15 billion, bolstering its global accreditations including US-FDA, UK-MHRA and WHO-GMP for multiple facilities, and advancing R&D initiatives in innovative drug delivery and specialized therapies amid robust domestic and export demand as of fiscal year 2025.